ストックスクリーナーアプリを入手
6.55
2.83%
0.18
Relmada Therapeutics Inc (RLMD) 最新ニュース
Relmada Therapeutics bolsters Sepranolone Program with Michael Quirk as Senior Advisor - Indian Pharma Post
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program - Investing News Network
Relmada appoints Michael Quirk as senior advisor for sepranolone - Investing.com
Relmada appoints Michael Quirk as senior advisor for sepranolone By Investing.com - Investing.com UK
Relmada Therapeutics Appoints CNS Drug Development Veteran - GlobeNewswire
Venrock-affiliated funds hold 6.2% of Relmada (NASDAQ: RLMD) - Stock Titan
RLMD Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesSurprise Factor Analysis - newsline.com
RLMD: NDV-01 advances to phase III with strong data, broadening access and maintaining solid financials - TradingView
RLMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Mov - Benzinga
RLMD Stock Chart | RELMADA THERAPEUTICS INC (NASDAQ:RLMD) - ChartMill
Relmada Therapeutics, Inc.Common Stock (NQ: RLMD - FinancialContent
RLMD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Relmada executives to present at Jefferies healthcare conference - Investing.com UK
Relmada TherapeuticsIncreases authorized common stock to 200 million shares from 150 million - marketscreener.com
Relmada (NASDAQ: RLMD) holders back higher share cap and equity plan - Stock Titan
Relmada executives to present at Jefferies healthcare conference By Investing.com - Investing.com Australia
Relmada Therapeutics (RLMD) to Present at the Jefferies Global Healthcare Conference - StreetInsider
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Relmada Therapeutics Increases Authorized Shares After Shareholder Vote - TipRanks
Relmada Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Relmada Therapeutics (RLMD) Edges Higher as Stock Holds Above Key SupportForce Index - newsline.com
Relmada Therapeutics Inc. (RLMD) Slips 2.36% as Stock Tests Key Support LevelsMA Crossover - The Legal Advocate
RLMD News | RELMADA THERAPEUTICS INC (NASDAQ:RLMD) - ChartMill
Earnings call transcript: Relmada Therapeutics Q1 2026 sees stock dip despite strong cash position By Investing.com - Investing.com South Africa
Earnings call transcript: Relmada Therapeutics Q1 2026 sees stock dip despite strong cash position - Investing.com
Relmada targets mid-2026 phase 3 RESCUE start backed by $234M cash runway through 2029 - MSN
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Relmada Therapeutics Charts Ambitious NDV-01 Phase 3 Path - TipRanks
Relmada Therapeutics Inc files for mixed shelf offering, size not disclosedSEC filing - marketscreener.com
Relmada Therapeutics Q1 earnings call highlights - MSN
Relmada Therapeutics (NASDAQ: RLMD) registers 29.5M shares tied to $160M deal - Stock Titan
Relmada Therapeutics Q1 Loss per Share Narrows - Moomoo
Adage Capital reports 4.54% stake in Relmada Therapeutics (NASDAQ: RLMD) - Stock Titan
Q1 2026 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Piper Sandler Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call Transcript - Insider Monkey
Relmada Therapeutics Reports Strong Q1 2026 Results, Highlights Positive NDV-01 Phase 2 Data in Bladder Cancer and Plans for Phase 3 RESCUE Program - Minichart
Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights - GuruFocus
Is Relmada Therapeutics (RLMD) Fairly Valued After Q1 2026? EPS: - GuruFocus
Relmada Therapeutics Q1 Earnings Call Highlights - sharewise.com
Transcript : Relmada Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026 - marketscreener.com
Relmada Highlights NDV-01 Phase 2 Data, Phase 3 Plans - TipRanks
Earnings call transcript: Relmada Therapeutics Q1 2026 results reveal mixed performance - Investing.com Nigeria
RLMD: NDV-01 shows best-in-class efficacy in NMIBC; cash and patent position support long-term growth - TradingView
RLMD: NDV-01 demonstrates high efficacy in NMIBC, with robust financials supporting late-stage trials - TradingView
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Investing News Network
Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call - Benzinga
Relmada (NASDAQ: RLMD) boosts cash with $160M PIPE and NDV-01 data - Stock Titan
RLMD: NDV-01 demonstrates high response rates in NMIBC, with pivotal trials and strong financial backing ahead - TradingView
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):